Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
53.8 USD | +0.13% | -1.83% | -13.67% |
Apr. 18 | Citigroup Adjusts CRISPR Therapeutics' Price Target to $89 From $88, Keeps Buy Rating | MT |
Apr. 17 | Crispr Therapeutics Insider Sold Shares Worth $1,173,232, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.67% | 4.56B | |
+1.94% | 42.59B | |
+8.32% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.75% | 24.81B | |
-24.12% | 18.17B | |
+28.83% | 12.05B | |
-2.99% | 11.7B | |
+6.91% | 11.1B |
- Stock Market
- Equities
- CRSP Stock
- News CRISPR Therapeutics AG
- Barclays Adjusts Price Target on Crispr Therapeutics to $148 from $160, Keeps Overweight Rating